Prostate cancer modality time trend analyses from 1973 to 2004: A surveillance, epidemiology, and end results registry analysis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 2, 2010, Pages 168-172

  Jani, Ashesh B ^a   Johnstone, Peter A S ^b   Liauw, Stanley L ^c   Master, Viraj A ^a   Rossi, Peter J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Outcomes; Prostate cancer; Prostatectomy; Radiotherapy; SEER

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER REGISTRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; TREND STUDY;

BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951060646     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181a44ebe     Document Type: Article

References (30)

1. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1045-1053.
2. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710-1721.
3. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice- localized prostate cancer. N Engl J Med. 2007;357:2696-2705.
4. Smith JA Jr. Radical prostatectomy for low risk carcinoma of the prostate. World J Urol. 2008;26:443-446.
5. Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol. 2008;18:48-57.
6. Mangar SA, Huddart RA, Parker CC, et al. Technological advances in radiotherapy for the treatment of localized prostate cancer. Eur J Cancer. 2005;41:908-921.
7. Soto DE, McLaughlin PW. Combined permanent implant and external-beam radiation therapy for prostate cancer. Semin Radiat Oncol. 2008;18:23-34.
8. Sahgal A, Roach M III. Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application. Nat Clin Pract Urol. 2007;4:658-670.
9. Jani AB, Hellman S. Early prostate cancer: hedonic prices model of providerpatient interactions and decisions. Int J Radiat Oncol Biol Phys. 2008;70: 1158-1168.
10. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146-8151.
11. Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007; 178(3 pt 2):S14-S19.
12. Cooperberg MR, Cowan J, Broering JM, et al. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008;26:211-218.
13. Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170:S21-S27.
14. Hanks GE, Hanlon A, Schultheiss T, et al. Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol. 1994;152(5 pt 2):1775-1780.
15. Zelefsky MJ, Moughan J, Owen J, et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1053-1061.
16. Lee WR, Moughan J, Owen JB, et al. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer. 2003;98:1987-1994.
17. National Cancer Institute. Surveillance, Epidemiology, and End Results. SEER*Stat 6.4. Available at: http://seer.cancer.gov/seerstat/.
18. Smart CR. The results of prostate carcinoma screening in the US as reflected in the surveillance, epidemiology, and end results program. Cancer. 1997;80:1835-1844.
19. Jani AB, Master VA, Rossi PJ, et al. Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer Prostatic Dis. 2007;10:347-351.
20. Jani AB, Johnstone PA, Liauw SL, et al. Age and grade trends in prostate cancer (1974 -2003): a surveillance, epidemiology, and end results registry analysis. Am J Clin Oncol. 2008;31:375-378.
21. Johnstone PA, Riffenburgh RH, Rossi PJ, et al. Applying population dynamics modeling to patients with lymph node positive prostate cancer. J Urol. 2007;178:1952-1955.
22. Copeland LA, Elshaikh MA, Jackson J, et al. Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma. Cancer. 2005;104:1372-1380.
23. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.
24. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th Ed. New York, NY: Springer-Verlag; 2002.
25. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. East Norwalk, CT: Prentice Hall; 1990.
26. Carlin BP, Louis, TA. Bayes and Empirical Bayes Methods for Data Analysis. 2nd ed. Boca Raton, FL: Chapman and Hall; 2000.
27. Jani AB. Management strategies for locally advanced prostate cancer. Drugs Aging. 2006;23:119-129.
28. D'Amico AV, Chen MH, Catalona WJ, et al. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007;110:56-61.
29. Cooper GS, Virnig B, Klabunde CN, et al. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(suppl 8):IV-43-IV-8.
30. Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40(suppl 8):IV-49 -IV-54.